Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22176372 | 0.75 | L3MBTL4 (0.34) | L3MBTL4L3MBTL3TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL23969240 | 0.75 | L3MBTL4 (0.40) | L3MBTL4L3MBTL3TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL22176126 | 0.73 | ALDH1A1 (0.41) | L3MBTL4L3MBTL3TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL24633833 | 0.72 | TP53 (0.38) | TDP1ALDH1A1LMNAMAPT | |
| SCHEMBL26515833 | 0.72 | RAB9A (0.45) | L3MBTL4L3MBTL3ALDH1A1L3MBTL1MAPT | |
| SCHEMBL25989384 | 0.70 | L3MBTL4 (0.38) | L3MBTL4L3MBTL3TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL12288721 | 0.70 | ALDH1A3 (0.39) | TDP1ALDH1A1L3MBTL1HPGDLMNA | |
| SCHEMBL4311553 | 0.70 | MAPT (0.37) | MAPT | |
| SCHEMBL19142861 | 0.69 | TAAR1 (0.37) | L3MBTL4L3MBTL3TDP1ALDH1A1HPGD | |
| SCHEMBL22877218 | 0.67 | CYP3A4 (0.33) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020138015-A1 | PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | 大正製薬株式会社 | 2020-07-02 | — | — | WO | disclosed |